Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
| Autor: | Hamed Goodarzi, Mohammad Heiat, Reza Ranjbar, Elnaz Saeidi, Farhad Safarpoor Dehkordi, Payam Ghasemi-Dehkordi, Amirhossein Sheikhshahrokh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
viruses
medicine.medical_treatment ACE2 Review Article Virus S protein 03 medical and health sciences 0302 clinical medicine Immune system medicine 030212 general & internal medicine skin and connective tissue diseases Host cell surface Vaccines 030505 public health biology Transmission (medicine) lcsh:Public aspects of medicine fungi Public Health Environmental and Occupational Health COVID-19 virus diseases lcsh:RA1-1270 Immunotherapy Virology respiratory tract diseases Vaccination Viral replication biology.protein Antibody 0305 other medical science |
| Zdroj: | Iranian Journal of Public Health, Vol 49, Iss Supple 1 (2020) Iranian Journal of Public Health |
| ISSN: | 2251-6093 2251-6085 |
| DOI: | 10.18502/ijph.v49is1.3666 |
| Popis: | COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|